InMed appoints Michael Woudenberg as COO effective July 15, 2022

InMed Pharmaceuticals Inc.

Michael Woudenberg appointed Chief Operating Officer, effective July 15, 2022.
Previously served as SVP of Chemistry, Manufacturing and Controls.
Employment agreement provides C$300,000 annual base salary.
Eligible for annual discretionary bonus targeted at 40% of base salary.
Woudenberg has over 20 years of drug development and GMP manufacturing experience.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Michael Woudenberg

Chief Operating Officer

INM · InMed Pharmaceuticals Inc.

Effective: 2022-07-15
Filed: July 20, 2022, 7:59 PM ET

On July 18, 2022, InMed Pharmaceuticals Inc. (the “Company”) issued a press release to announce that it has appointed Mr. Michael Woudenberg as the Company’s Chief Operating Officer effective July 15, 2022 (the “Effective Date”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Michael Woudenberg was appointed as Chief Operating Officer at InMed Pharmaceuticals Inc..

Action: appointed
Role: Chief Operating Officer

Exact text from the filing

On July 18, 2022, InMed Pharmaceuticals Inc. (the “Company”) issued a press release to announce that it has appointed Mr. Michael Woudenberg as the Company’s Chief Operating Officer effective July 15, 2022 (the “Effective Date”).

View on SEC.gov

InMed Pharmaceuticals Inc. filing history →

Source: SEC EDGAR

accession 0001213900-22-040385

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.